title: Alterations of peripheral blood CD5+ B cells in inflammatory bowel disease.
abstract: OBJECTIVE
  CD5(+) B cells comprise a unique subset of B cells that modulates innate as well as autoimmune systems. The aim of this study was to investigate alterations of the circulating CD5(+) B-cell subset in patients with inflammatory bowel disease (IBD) by evaluating various clinical parameters, including therapeutic regimens.
  
  
  METHODS
  Thirty-four patients with ulcerative colitis (UC), 19 patients with Crohn's disease (CD), and 46 healthy control subjects were enrolled in this study. CD5(+) B cells in peripheral blood collected from each subject were analyzed by flow cytometry. Multiple regression analysis was carried out to evaluate the factors related to the circulating CD5(+) B-cell subset in the IBD patients. In an in vitro examination, dexamethasone-induced apoptosis in peripheral blood B cells was examined by detecting cell surface binding of the annexin-V antibody.
  
  
  RESULTS
  Age and gender in the control subjects did not influence the circulating CD5(+) B-cell subset. Multiple regression analysis showed that the presence of UC, corticosteroid therapy, and number of white blood cells in peripheral blood each had a significant influence in decreasing the number of circulating CD5(+) B cells in the IBD patients. Furthermore, in vitro results showed that dexamethasone treatment significantly induced apoptosis in CD5(+) B cells, though apoptosis was similarly observed in CD5(-) B cells.
  
  
  CONCLUSIONS
  CD5(+) B cells may be involved in the pathogenesis of UC, and modulation of this subset by corticosteroid therapy may play a role in the treatment of IBD patients.
authors.affiliation: Department of Internal Medicine II, Shimane University School of Medicine, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Mishima
authors.forename: Shunji
authors.initials: S
authors.lastname: Ishihara
authors.forename: Yuji
authors.initials: Y
authors.lastname: Amano
authors.forename: Naoki
authors.initials: N
authors.lastname: Oshima
authors.forename: Chikara
authors.initials: C
authors.lastname: Kadota
authors.forename: Aya
authors.initials: A
authors.lastname: Otani
authors.forename: Ichiro
authors.initials: I
authors.lastname: Moriyama
authors.forename: Yong-Yu
authors.initials: YY
authors.lastname: Li
authors.forename: M M
authors.initials: MM
authors.lastname: Aziz
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016175:B-Lymphocyte Subsets / Q000378:metabolism*; D001402:B-Lymphocytes / Q000378:metabolism*; D018956:CD5 Antigens / Q000097:blood* / Q000276:immunology; D016022:Case-Control Studies; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D018956:CD5 Antigens; D005938:Glucocorticoids